OBI 3424

Drug Profile

OBI 3424

Alternative Names: OBI-3424; TH-3424

Latest Information Update: 28 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Threshold Pharmaceuticals
  • Developer Ascenta Pharmaceuticals; National Cancer Institute (USA); Threshold Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action AKR1C3 protein inhibitors; Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Hepatocellular carcinoma; Prostate cancer

Most Recent Events

  • 24 Oct 2017 Pharmacodynamics and safety data from a preclinical study in Acute lymphoblastic leukaemia presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 18 Jul 2017 OBI Pharma announces intention to submit IND application for Cancer in the first quarter of 2018
  • 01 Jun 2017 OBI Pharma acquires TH 3424 from Threshold Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top